Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge

Vaccine

Volumn 24, Issue 37-39, 2006, Pages 6340-6350

  Vipond, Julia ^a   Vipond, Richard ^a   Allen Vercoe, Emma ^a   Clark, Simon O ^a   Hatch, Graham J ^a   Gooch, Karen E ^a   Bacon, Joanna ^a   Hampshire, Toby ^a   Shuttleworth, Helen ^a   Minton, Nigel P ^a   Blake, Karen ^a   Williams, Ann ^a   Marsh, Philip D ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

DNA vaccine; Guinea pig; Mycobacterium tuberculosis

Indexed keywords

ACYLTRANSFERASE; BCG VACCINE; DNA VACCINE; METALLOPROTEINASE; PLASMID DNA; SODIUM CHLORIDE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GUINEA PIG; IMMUNE RESPONSE; INFECTION PREVENTION; LUNG; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TH1 CELL; TUBERCULOSIS;

AEROSOLS; ANIMALS; BCG VACCINE; FEMALE; GUINEA PIGS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA;

EID: 33747331970     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.025     Document Type: Article

References (54)

1. Andersen P., and Doherty T.M. TB subunit vaccines-putting the pieces together. Microbes Infect 7 5-6 (2005) 911-921
2. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 8986 (1995) 1339-1345
3. McMurray D.N. Recent progress in the development and testing of vaccines against human tuberculosis. Int J Parasitol 33 5-6 (2003) 547-554
4. Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 6685 (1998) 537-544
5. Brennan M.J. The tuberculosis vaccine challenge. Tuberculosis (Edinburgh) 85 1-2 (2005) 7-12
6. Izzo A., Brandt L., Lasco T., Kipnis A.-P., and Orme I. NIH pre-clinical screening program: overview and current status. Tuberculosis (Edinburgh) 85 1-2 (2005) 25-28
7. Doria-Rose N.A., and Haigwood N. DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods 31 3 (2003) 207-216
8. Tascon R.E., Colston M.J., Ragno S., Stavropoulos E., Gregory D., and Lowrie D.B. Vaccination against tuberculosis by DNA injection. Nat Med 2 8 (1996) 888-892
9. Huygen K., Content J., Denis O., Montgomery D.L., Yawman A.M., Deck R.R., et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 2 8 (1996) 893-898
10. Lowrie D.B., Silva C.L., Colston M.J., Ragno S., and Tascon R.E. Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 15 8 (1997) 834-838
11. Reed S.G., Alderson M.R., Dalemans W., Lobet Y., and Skeiky Y.A.W. Prospects for a better vaccine against tuberculosis. Tuberculosis (Edinburgh) 83 (2003) 213-219
12. Burke R.L., Pachl C., Quiroga M., Rosenberg S., Haigwood N., Nordfang O., et al. The functional domains of coagulation factor VIII:C. J Biol Chem 261 27 (1986) 12574-12578
13. Chapman B.S., Thayer R.M., Vincent K.A., and Haigwood N.L. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucl Acids Res 19 14 (1991) 3979-3986
14. Leitner W.W., Seguin M.C., Ballou W.R., Seitz J.P., Schultz A.M., Sheehy M.J., et al. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J Immunol 159 12 (1997) 6112-6119
15. Berg D.T., and Grinnell B.W. Signal and propeptide processing of human tissue plasminogen activator: activity of a pro-tPA derivative. Biochem Biophys Res Commun 179 3 (1991) 1289-1296
16. Baldwin S.L., D'Souza C.D., Orme I.M., Liu M.A., Huygen K., Denis O., et al. Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. Tuber Lung Dis 79 4 (1999) 251-259
17. Kohne C., Johnson A., Tom S., Peers D.H., Gehant R.L., Hotaling T.A., et al. Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activator. J Cell Biochem 75 3 (1999) 446-461
18. Baldwin S.L., D'Souza C.D., Roberts A.D., Kelly B.P., Frank A.A., Liu M.A., et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 66 6 (1998) 2951-2959
19. Horwitz M.A., and Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 71 4 (2003) 1672-1679
20. Lasco T.M., Cassone L., Kamohara H., Yoshimura T., and McMurray D.N. Evaluating the role of tumor necrosis factor-alpha in experimental pulmonary tuberculosis in the guinea pig. Tuberculosis (Edinburgh) 85 4 (2005) 245-258
21. Olsen A.W., Williams A., Okkels L.M., Hatch G., and Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of Antigen85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 72 10 (2004) 6148-6150
22. Orme I.M. Current progress in tuberculosis vaccine development. Vaccine 23 17 (2005) 2105-2108
23. Orme I.M., McMurray D.N., and Belisle J.T. Tuberculosis vaccine development: recent progress. Trends Microbiol 9 3 (2001) 115-118
24. Williams A., Hatch G.J., Clark S.O., Gooch K.E., Hatch K.A., Hall G.A., et al. Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinburgh) 85 1-2 (2005) 29-38
25. McMurray D.N. Guinea pig model of tuberculosis. In: Bloom B.R. (Ed). Tuberculosis: pathogenesis, protection and control (1994), ASM Press, Washington, DC 135-147
26. Valdivia R.H., and Falkow S. Fluorescence-based isolation of bacterial genes expressed within host cells. Science 277 5334 (1997) 2007-2011
27. Bacon J.B., James B.W., Wernisch L., Williams A., Morley K.A., Hatch G.J., et al. The influence of reduced oxygen availability on pathogenicity and gene expression in Mycobacterium tuberculosis. Tuberculosis (Edinburgh) 84 3-4 (2004) 205-217
28. Hampshire T., Soneji S., Bacon J., James B.W., Hinds J., Laing K., et al. Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms?. Tuberculosis (Edinburgh) 84 3-4 (2004) 228-238
29. Ausebel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., et al. Short protocols in molecular microbiology (1992), Wiley, Chichester, USA
30. Shuttleworth H., Ambrose E., Griffiths K., MacDonald-Fyall J., Minton N., Rawkins A., et al. Identification of novel TB vaccine candidates by differential fluorescence induction. Tuberculosis (Edinburgh) 82 4-5 (2002) 209
31. http://www.chem.agilent.com/scripts/pds.asp?lpage=27881
32. Nielsen H., Engelbrecht J., Brunak S., and von Heijne G. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng 10 1 (1997) 1-6
33. Williams A., Davies A., Marsh P.D., Chambers M.A., and Hewinson R.G. Comparison of the protective efficacy of Bacille Calmette-Guerin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis. Clin Infect Dis 30 Suppl 3 (2000) S299-S301
34. Karlin S., and Mrazek J. Predicted highly expressed genes of diverse prokaryotic genomes. J Bact 182 18 (2000) 5238-5250
35. Mustafa A.S., Oftung F., Amoudy H.A., Madi N.M., Abal A.T., Shaban F., et al. Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines. Clin Infect Dis 30 Suppl 3 (2000) S201-S205
36. Sassetti C.M., Boyd D.H., and Rubin E.J. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Micro 48 1 (2003) 77-84
37. H in Mycobacterium tuberculosis global gene expression. Mol Microbiol 45 2 (2002) 365-374
38. Schnappinger D., Ehrt S., Voskuil M.I., Liu Y., Mangan J.A., Monahan I.M., et al. Transcriptome adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J Exp Med 198 5 (2003) 693-704
39. Howard R.J. Vaccination against malaria: recent advances and the problems of antigenic diversity and other parasite evasion mechanisms. Int J Parasitol 17 1 (1987) 17-29
40. Okkels L.M., Brock I., Follmann F., Agger E.M., Arend S.M., Ottenhoff T.M., et al. PPE protein (Rv3873) from DNA segment RD1 of Mycobacterium tuberculosis: strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family. Infect Immun 71 11 (2003) 6116-6123
41. Delogu G., and Brennan M.J. Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis. Infect Immun 69 9 (2001) 5606-5611
42. Eswaramoorthy S., Kumaran D., and Swaminathan S. A novel mechanism for Clostridium botulinum neurotoxin inhibition. Biochemistry 41 31 (2002) 9795-9802
43. Kochi S.K., Schiavo G., Mock M., and Montecucco C. Zinc content of the Bacillus anthracis lethal factor. FEMS Microbiol Lett 124 3 (1994) 343-348
44. Kooi C., Corbett C.R., and Sokol P.A. Functional analysis of the Burkholderia cenocepacia ZmpA metalloprotease. J Bacteriol 187 13 (2005) 4421-4429
45. Shoop W.L., Xiong Y., Wiltsie J., Woods A., Guo J., Pivnichny J.V., et al. Anthrax lethal factor inhibition. Proc Natl Acad Sci 102 22 (2005) 7958-7963
46. Derrick S.C., Repique C., Snoy P., Yang A.L., and Morris S. Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis. Infect Immun 72 3 (2004) 1685-1692
47. Lima K.M., dos Santos S.A., Santos R.R., Brandao I.T., Rodrigues J.M., and Silva C.L. Efficacy of DNA-hsp65 vaccination for tuberculosis varies with method of DNA introduction in vivo. Vaccine 22 1 (2003) 49-56
48. Wang R., Doolan D.L., Le T.P., Hedstrom, Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 5388 (1998) 476-480
49. Brandt L., Skeiky Y.A.W., Alderson M.R., Lobet Y., Dalemans W., Turner O.C., et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by co administration with the Mycobacterium tuberculosis 72-kDa fusion polypeptide Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72 11 (2004) 6622-6632
50. Skeiky Y.A.W., Alderson M.A., Ovendale P.J., Guderian J.A., Brandt L., Dillon D.C., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172 12 (2004) 7618-7628
51. Sugawara I., Yamada H., Udagawa T., and Huygen K. Vaccination of guinea pigs with DNA encoding Ag85A by gene gun bombardment. Tuberculosis (Edinburgh) 83 (2003) 331-337
52. Mollenkopf H.J., Grode L., Mattow J., Stein M., Mann P., Knapp B., et al. Application of Mycobacterial proteomics to vaccine design: Improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis. Infect Immun 72 11 (2004) 6471-6479
53. Giri M., Ugen K.E., and Weiner D.B. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev 17 2 (2004) 370-389
54. Moore A.C., and Hill A.V.S. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 199 (2004) 126-143